‘la Caixa’, throught their venture capital arm Caixa Capital Risc, and Inveready have invested €2.7 million in aptaTargets, which will allow this biopharmaceutical company to complete the preclinical phase and move into phase I and II clinical trials on its first drug candidate (ApTOLL) to treat acute ischemic stroke. Press release